Pharmacological and therapeutic properties of valproate: A summary after 35 years of clinical experience

CNS Drugs

Volumn 16, Issue 10, 2002, Pages 695-714

  Perucca, Emilio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CYTOCHROME P450; ETHOSUXIMIDE; EXCITATORY AMINO ACID; FELBAMATE; LAMOTRIGINE; NEUROLEPTIC AGENT; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SODIUM CHANNEL; VALPROIC ACID; ZIDOVUDINE;

BRAIN DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG OXIDATION; DRUG SOLUBILITY; EPILEPSY; GABAERGIC SYSTEM; GABAERGIC TRANSMISSION; GASTROINTESTINAL SYMPTOM; GENERALIZED EPILEPSY; GRAND MAL EPILEPSY; HUMAN; HYPERAMMONEMIA; LIVER TOXICITY; MYOCLONUS EPILEPSY; PANCREATITIS; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC TRANSMISSION; SIDE EFFECT; SUSTAINED RELEASE PREPARATION; TERATOGENICITY; THROMBOCYTE ANOMALY; TREATMENT INDICATION; TREMOR; WEIGHT GAIN;

EID: 0036401554     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200216100-00004     Document Type: Review

References (167)

1. Hauser WA, Hesdorffer DC. Epilepsy: frequency, causes and consequences. New York: Demos, 1990
2. Annegers JF. Epidemiology of epilepsy. In: Wyllie E, editor. The treatment of epilepsy: principles and practice. 2nd ed. Baltimore (MD): Williams & Wilkins, 1997: 165-72
3. Hauser WA, Annegers JF, Kurland LT. Prevalence of epilepsy in Rochester, Minnesota, 1940-80. Epilepsia 1991; 32: 429-45
4. Perucca E, Beghi E, Dulac O, et al. Assessing risk to benefit ratio in antiepileptic drug therapy. Epilepsy Res 2000; 41: 107-39
5. Moinier H, Carraz G, Moinier Y, et al. Propriété pharmacodynamique de la site N-dipropylacétique. Mémoire: propriété anti-épileptique. Thérapie 1963; 18: 435-8
6. Löscher W. Valproate: reappraisal of its pharmacodynamic properties and mechanism of action. Prog Neurobiol 1999; 58: 31-59
7. Löscher W. Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain. Neurochem Res 1993; 18: 485-502
8. Gean PW, Huang CC, Hung CR, et al. Valproic acid suppresses the synaptic response mediated by the NMDA receptors in rat amygdalar slices. Brain Res Bull 1994; 33 (3): 333-6
9. McLean MJ, Macdonald RL. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 1986; 237 (3): 1001-11
10. Davis R, Peters DH, McTavish D. Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994; 47: 332-72
11. Perucca E, Gatti G, Frigo GM, et al. Pharmacokinetics of valproic acid after oral and intravenous administration. Br J Clin Pharmacol 1978; 5: 313-8
12. Perucca E, Gatti G, Frigo GM, et al. Disposition of sodium valproate in epileptic patients. Br J Clin Pharmacol 1978; 5: 495-9
13. Gugler R, von Unruh GE. Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 1980; 5: 67-83
14. Zaccara G, Messori A, Moroni F. Clinical pharmacokinetics of valproic acid: 1988. Clin Pharmacokinet 1988; 55: 367-89
15. Barre J, Berger Y. Pharmacokinetics of a newly developed sustained-release form of sodium valproate. In: Chadwick D, editor. Proceedings of the Fourth International Symposium on Sodium Valproate and Epilepsy, International Congress and Symposium Series No. 152. London: Royal Society of Medicine Services, 1989: 178-84
16. Levy RH, Cenraud B, Loiseau P, et al. Meal-dependent absorption of enteric coated sodium valproate. Epilepsia 1980; 21: 273-80
17. Royer-Morrot MJ, Zhiri A, Jacob F, et al. Influence of food intake on the pharmacokinetics of a sustained release formulation of sodium valproate. Biopharm Drug Dispos 1993; 14: 511-8
18. Cramer JA, Mattson RH. Valproic acid: in vitro plasma protein binding and interaction with phenytoin. Ther Drug Monit 1979; 1: 105-16
19. Gram L, Flachs H, Wurtz-Jorgensen A, et al. Sodium valproate, serum level and clinical effect in epilepsy: a controlled study. Epilepsia 1979; 20: 303-12
20. Bowdle TA, Patel IH, Levy RH, et al. Valproic acid dosage and plasma protein binding and clearance. Clin Pharmacol Ther 1980; 28: 486-92
21. Shen DD, Ojemann GA, Rappaport RL, et al. Low and variable presence of valproic acid in human brain. Neurology 1992; 42:582-5
22. Levy RH, Shen D, Abbott F, et al. Valproic acid: chemistry, biotransformation and pharmacokinetics. In: Levy RH, Mattson BS, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2002: 780-800
23. Frey HH, Löscher W. Distribution of valproate across the interface between blood and cerebrospinal fluid. Neuropharmacology 1978; 17: 637-42
24. Löscher W, Frey HH. Kinetics of penetration of common antiepileptic drugs into cerebrospinal fluid. Epilepsia 1984; 25: 346-52
25. Perucca E, Grimaldi R, Gatti G, et al. Pharmacokinetics of valproic acid in the elderly. Br J Clin Pharmacol 1984; 17: 665-9
26. Koerner M, Yerby M, Friel P, et al. Valproic acid disposition and protein binding in pregnancy. Ther Drug Monit 1989; 11: 228-30
27. Henriksen O, Johannessen SI. Clinical and pharmacokinetic observations on sodium valproate: a 5-year follow-up study in 100 children with epilepsy. Acta Neurol Scand 1982; 65: 504-23
28. Hoffmann F, von Unruh GE, Jancik BC. Valproic acid disposition in epileptic patients during combined antiepileptic maintenance therapy. Eur J Clin Pharmacol 1981; 19: 383-5
29. Levy RH, Koch KM. Drug interactions with valproic acid. Drugs 1982; 24: 543-56
30. May TW, Rambeck B. Serum concentration of valproic acid: influence of dose and co-medication. Ther Drug Monit 1985; 7:387-90
31. Patsalos PN, Froscher W, Pisani F, et al. The importance of drug interactions in epilepsy therapy. Epilepsia 2002; 43: 365-85
32. Scheyer RD. Valproic acid: drug interactions. In: Levy RH, Mattson BS, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2002: 801-7
33. Bruni J, Wilder BJ, Perchalski RJ, et al. Valproic acid and plasma levels of phenobarbital. Neurology 1980; 30: 94-7
34. Kanner AM, Frey M. Adding valproate to lamotrigine: a study of their pharmacokinetic interaction. Neurology 2000; 55: 588-91
35. Morris RG, Black AB, Lam E, et al. Clinical study of lamotrigine and valproic acid in patients with epilepsy: using a drug interaction to advantage? Ther Drug Monit 2000; 22: 656-60
36. McKee JW, Blacklaw J, Butler E, et al. Variability and clinical relevance of the interaction between sodium valproate and carbamazepine in epileptic patients. Epilepsy Res 1992; 11: 193-8
37. Pisani F, Fazio A, Oteri G, et al. Sodium valproate and valpromide: differential interactions with carbamazepine in epileptic patients. Epilepsia 1986; 27: 548-52
38. Robbins DK, Wedlund PJ, Kuhn R, et al. Inhibition of epoxide hydrolase by valproic acid in epileptic patients receiving carbamazepine. Br J Clin Pharmacol 1990; 29: 759-62
39. Anderson GD, Gidal BE, Kantor ED, et al. Lorazepam-valproate interaction: studies in normal subjects and isolated perfused rat liver. Epilepsia 1994; 35: 221-5
40. Lertora JJL, Rege AB, Greespan DL, et al. Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1994; 56: 272-8
41. Wong SL, Cavanaugh J, Shi H, et al. Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics. Clin Pharmacol Ther 1996; 60: 48-53
42. Tartara A, Galimberti CA, Manni R, et al. Differential effects of valproic acid and enzyme inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. Br J Clin Pharmacol 1991; 32: 335-40
43. Pisani F, Narbone MC, Trunfio C, et al. Valproic acid-ethosuximide interaction: a pharmacokinetic study. Epilepsia 1984; 25: 229-33
44. Tsanaclis LM, Allen J, Perucca E, et al. Effect of valproate on free plasma phenytoin concentrations. Br J Pharmacol 1984; 18: 17-20
45. Perucca E, Hebdige S, Frigo GM, et al. Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects. Clin Pharmacol Ther 1980; 28: 779-89
46. Rowan AJ, Meijer JWA, de Beer-Pawlikowski N, et al. Valproate-ethosuximide combination therapy for refractory absence seizures. Arch Neurol 1983; 40: 797-802
47. Perucca E. Pharmacological principles as a basis for polytherapy. Acta Neurol Scand Suppl 1995; 162: 31-4
48. Brodie MJ, Yuen AWC. Lamotrigine substitution study: evidence for synergism with sodium valproate: 105 Study Group. Epilepsy Res 1997; 26: 423-32
49. Pisani F, Oteri G, Russo MF, et al. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 1999; 40: 1141-6
50. Panayiotopoulos CP, Ferrie CD, Knott C, et al. Interaction of lamotrigine with sodium valproate [letter]. Lancet 1993; 341: 445
51. Bergmann A, Schmidt D, Hutt HJ, et al. Epilepsietherapie mit retardierter valproinsäure: erfahrungen mit 1172 patienten [Results of a pragmatic study on 1172 patients treated with Depakine Chrono]. Aktuelle Neurol 1999; 26: 121-6
52. Brasfield KH. Pilot study of divalproex sodium valproate versus valproic acid: drug acquisition costs versus all related costs. Curr Ther Res Clin Exp 1999; 60: 138-44
53. Cranor CW, Sawyer WT, Carson SW, et al. Clinical and economic impact of replacing divalproex sodium with valproic acid. Am J Health Syst Pharm 1997; 54: 1716-22
54. Perucca E, Dulac O, Shorvon S, et al. Harnessing the clinical potential of antiepileptic drug therapy: dosage optimisation. CNS Drugs 2001; 15: 209-621
55. Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001; 42: 1255-60
56. Covanis A, Jeavons PM. Once daily sodium valproate in the treatment of epilepsy. Dev Med Child Neurol 1980; 22: 202-4
57. Richens A, Davidson DLW, Cartlidge NEF, et al. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy: the Adult EPITEG Collaborative Group. J Neurol Neurosurg 1994; 57: 682-7
58. Commission on Antiepileptic Drugs, International League against Epilepsy. Guidelines for therapeutic monitoring on antiepileptic drugs. Epilepsia 1993; 34: 585-7
59. Lundberg B, Nergardh A, Boreus LO. Plasma concentrations of valproate during maintenance therapy in epileptic children. J Neurol 1982; 228: 133-41
60. Pinder RM, Brogden RN, Speight TM, et al. Sodium valproate: a review of its pharmacological properties and therapeutic efficacy in epilepsy. Drugs 1977; 13: 81-123
61. Seino M. A comment on the efficacy of valproate in the treatment of partial seizures. Epilepsia 1994; 35 Suppl. 5: S101-4
62. Turnbull DM, Howel D, Rawlins MD, et al. Which drug for the adult epileptic patient: phenytoin or valproate? BMJ 1985; 290: 815-9
63. Callaghan N, Kenny RA, O'Neill B, et al. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. J Neurol Neurosurg Psychiatry 1985; 48: 639-44
64. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults: the Department of the Veteran Affairs Epilepsy Cooperative Study Group. N Engl J Med 1992; 327: 765-71
65. Ramsay RE, Wilder BJ, Murphy JV, et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalised tonic-clonic seizures. J Epilepsy 1992; 5: 55-60
66. Heller AJ, Chesterman P, Elwes RDC, et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. J Neurol Neurosurg Psychiatry 1995; 58: 44-50
67. Verity CM, Hosking G, Easter DJ. A multicenter comparative trial of sodium valproate and carbamazepine in paediatric epilepsy: the Paediatric EPITEG Collaborative Group. Dev Med Child Neurol 1995; 37: 97-108
68. De Silva M, MacArdle B, McGowan M, et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996; 347: 709-13
69. Thilothammal N, Banu K, Ratnam RS. Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double-blind study. Indian Pediatr 1996; 33: 549-55
70. Turnbull DM, Rawlins MD, Weightman D, et al. A comparison of phenytoin and valproate in previously untreated adult epileptic patients. J Neurol Neurosurg Psychiatry 1982; 45: 55-9
71. Reynolds EH, Heller AJ, Chadwick D. Valproate versus carbamazepine for seizures. N Engl J Med 1993; 328: 207-8
72. Monfort JC. Valproate versus carbamazepine for seizures. N Engl J Med 1993; 328: 208-9
73. Beydoun A, Sackellares JC, Shu V. Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: a double-blind, concentration-response design clinical trial. Depakote Monotherapy for Partial Seizures Study Group. Neurology 1997; 48 (1): 182-8
74. Richens A, Ahmad S. Controlled trial of sodium valproate in severe epilepsy. BMJ 1970; 4: 73-6
75. Gram L, Rasmussen KE, Flachs H, et al. Valproate sodium: a controlled clinical trial including monitoring of serum levels. Epilepsia 1977; 18: 141-8
76. Tudur Smith C, Marson AG, Williamson PR. Phenytoin versus valproate monotherapy for partial onset seizures and generalized onset tonic-clonic seizures. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 3. Oxford: Oxford Update Software, 2000
77. Marson AG, Williamson PR, Clough H, et al. Carbamazepine versus valproate monotherapy for epilepsy: a meta-analysis. Epilepsia 2002; 43: 505-13
78. Christe W, Kramer G, Vigonius U, et al. A double-blind, controlled clinical trial of oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997; 26: 451-60
79. Perucca E, Tomson T. Monotherapy trials with the new antiepileptic drugs: study designs, practical relevance and ethical implications. Epilepsy Res 1999; 33: 247-62
80. Richens A, Perucca E. Clinical pharmacology and medical treatment. In: Laidlaw J, Richens A, Chadwick D, editors. A textbook of epilepsy. Edinburgh: Churchill-Livingstone, 1993: 495-559
81. Wolf P. Treatment of the idiopathic (primary) generalized epilepsies. In: Shorvon S, Dreifuss F, Fish D, et al., editors. The treatment of epilepsy. Oxford: Blackwell Science Ltd, 1996: 238-46
82. Perucca E. Principles of drug treatment. In: Shorvon SD, Dreifuss F, Fish D, et al., editors. The treatment of epilepsy. Oxford: Blackwell Science Ltd, 1996: 152-68
83. Perucca E. A reappraisal of valproate within today's therapeutic environment: with perspective of seizure types and syndromes. Seizure 2002. In press
84. Beghi E, Perucca E. The management of epilepsy in the 1990s: acquisitions, uncertainties, and perspectives for future research. Drugs 1995; 49: 680-94
85. Bauer J. Seizure-inducing effects of antiepileptic drugs: a review. Acta Neurol Scand 1996; 94: 367-77
86. Perucca E, Gram L, Avanzini G, et al. Antiepileptic drugs as a cause of worsening of seizures. Epilepsia 1998; 39: 5-17
87. Perucca E. Seizures provoked by antiepileptic drugs and by other medications. Neurologia 2001; 16 Suppl. 2: 43-51
88. Osorio I, Reed RC, Peltzer JN. Refractory idiopathic absence status epilepticus: a probable paradoxical effect of phenytoin and carbamazepine. Epilepsia 2000; 41: 887-94
89. Maheshwari MC, Jeavons PM. Proceedings: the effect of sodium valproate (Epilim) on the EEG [abstract]. Electro-encephalogr Clin Neurophysiol 1975; 39: 429
90. Braathen G, Theorell K, Persson A, et al. Valproate in the treatment of absence epilepsy in children: a study of dose-response relationships. Epilepsia 1988; 29: 548-52
91. Villarreal HJ, Wilder BJ, Willmore LJ, et al. Effect of valproic acid on spike and wave discharges in patients with absence seizures. Neurology 1978; 28: 886-91
92. Callaghan N, O'Hare J, O'Driscoll D, et al. Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Dev Med Child Neurol 1982; 24: 830-6
93. Sato S, White BG, Penry JK, et al. Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology 1982; 32: 157-63
94. Bourgeois B, Beaumanoir A, Blajev B, et al. Monotherapy with valproate in primary generalized epilepsies. Epilepsia 1987; 28 Suppl. 2: S8-11
95. Berkovic SF, Andermann F, Guberman A, et al. Valproate prevents the recurrence of absence status. Neurology 1989; 39: 1294-7
96. Covanis A, Gupta AK, Jeavons PM. Sodium valproate: monotherapy and polytherapy. Epilepsia 1982; 23: 582-93
97. Bachman DS. Use of valproic acid in treatment of infantile spasms. Arch Neurol 1982; 39: 49-52
98. Pavone L, Incorpora G, La Rosa M, et al. Treatment of infantile spasms with sodium dipropylacetic acid. Dev Med Child Neurol 1981; 23: 454-61
99. Siemes H, Spohr HL, Michael T, et al. Therapy of infantile spasms with valproate: results of a prospective study. Epilepsia 1988; 29: 553-60
100. Lee K, Melchior JC. Sodium valproate versus phenobarbital in the prophylactic treatment of febrile convulsions in childhood. Eur J Pediatr 1981; 137: 151-3
101. Herranz JL, Armijo JA, Arteaga R. Effectiveness and toxicity of phenobarbital, primidone, and sodium valproate in the prevention of febrile convulsions, controlled by plasma levels. Epilepsia 1984; 25: 89-95
102. Mamelle N, Mamelle JC, Plasse JC, et al. Prevention of recurrent febrile convulsions. A randomized therapeutic assay: sodium valproate, phenobarbital and placebo. Neuropediatrics 1984; 15: 37-42
103. Newton RW. Randomised controlled trials of phenobarbitone and valproate in febrile convulsions. Arch Dis Child 1988; 63: 1189-91
104. American Academy of Pediatrics Committee on Quality Improvements, Subcommittee on Febrile Seizures. Practice parameter: long-term treatment of the child with simple febrile seizures. Pediatrics 1999; 103: 1307-9
105. Bourgeois BFD. Valproic acid: clinical efficacy and use in epilepsy. In: Levy RH, Mattson BS, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2002: 808-17
106. Treiman DM. Status epilepticus. In: Laidlaw J, Richens A, Chadwick E, editors. A textbook of epilepsy. 4th ed. Edinburgh: Churchill Livingstone, 1993: 205-20
107. Morton LD, Towne AR, Garnett LK, et al. Safety and efficacy of intravenous valproate in status epilepticus. Epilepsia 2000; 41 Suppl. 7: 252
108. Katragadda SB, Aluri BC, Burdette DE. Intravenous administration of valproate in 12 patients [abstract]. Epilepsia 2000; 41 Suppl. 7: 3
109. Cantrell DT, Ramsay ER, Collings SD, et al. Rapid infusions of Depakon are safe and well tolerated [abstract]. Epilepsia 2000; 41 Suppl. 7: 253
110. Limdi NA, Faught E. The safety of rapid valproic acid infusion. Epilepsia 2000; 41: 1342-5
111. Giroud M, Gras D, Escousse A, et al. Use of injectable valproic acid in status epilepticus: a pilot study. Drug Invest 1993; 5: 154-9
112. Czapinski P, Terczynski A. Intravenous valproic acid administration in status epilepticus [in Polish]. Neurol Neurochir Pol 1998; 32: 11-22
113. Lowe MR, DeToledo JC, Vilavizza N, et al. Efficacy, safety, and tolerability of fast i.v. loading of valproate in patients with seizures and status epilepticus [abstract]. Epilepsia 1998; 39 Suppl. 6: 235
114. Sinha S, Naritoku DK. Intravenous valproate is well tolerated in unstable patients with status epilepticus. Neurology 2000; 55: 722-4
115. Hovinga CA, Chicella MF, Rose DF, et al. Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. Ann Pharmacother 1999; 33 (5): 579-84
116. Alfonso I, Alvarez LA, Gilman J, et al. Intravenous valproate dosing in neonates. J Child Neurol 2000; 15: 827-9
117. Haafiz A, Kissoon N. Status epilepticus: current concepts. Pediatr Emerg Care 1999; 15 (2): 119-29
118. Chez MG, Hammer MS, Loeffel M, et al. Clinical experience of three pediatric and one adult case of spike-and-wave status epilepticus treated with injectable valproic acid. J Child Neurol 1999; 14: 239-42
119. Alehan FK, Morton LD, Pellock JM. Treatment of absence status with intravenous valproate. Neurology 1999; 52: 889-90
120. Kaplan PW. Intravenous valproate treatment of generalized nonconvulsive status epilepticus. Clin Electroencephalogr 1999; 30: 1-4
121. Genton P, Gelisse P. Valproic acid: adverse effects. In: Levy RH, Mattson BS, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2002: 837-51
122. Schmidt D. Adverse effects of valproate. Epilepsia 1984; 15 Suppl. 1: S44-9
123. Wagner PG, Welton SR, Hammond CM. Gastrointestinal adverse effects with divalproex sodium and valproic acid. J Clin Psychiatry 2000; 61: 302-3
124. Thompson PJ, Trimble MR. Anticonvulsant and cognitive functions. Epilepsia 1982; 23: 531-44
125. Craig I, Tallis R. Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single-blind, randomized, comparative study. Epilepsia 1994; 35: 381-90
126. Perucca E. Evaluation of drug treatment outcome in epilepsy: a clinical perspective. Pharmacy World Science 1997; 19: 217-22
127. Battino D, Dukes MNG, Perucca E. Anticonvulsants. In: Dukes MNG, Aronson JK, editors. Meyler's side effects of drugs. 14th ed. Amsterdam: Elsevier Science BV, 2000: 164-97
128. Guerrini R, Belmonte A, Campichi R, et al. Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment. Epilepsia 1998; 39 (1): 27-32
129. Dinesen H, Gram L, Andersen T, et al. Weight gain during treatment with valproate. Acta Neurol Scand 1984; 70: 65-9
130. Isojarvi JIT, Tauboll E, Pakarinen AJ, et al. Altered ovarian function and cardiovascular risk factors in valproate-treated women. Am J Med 2001; 111: 290-6
131. Isojarvi JI, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993; 329: 1383-8
132. Frank S. Polycystic ovary syndrome: a changing perspective. Clin Endocrinol 1989; 31: 87-120
133. Chappell KA, Markowitz JS, Jackson CW. Is valproate pharmacotherapy associated with polycystic ovaries? Ann Pharmacother 1999; 33: 1211-6
134. Genton P, Bauer J, Duncan S, et al. On the association between valproate and policystic ovary syndrome. Epilepsia 2001; 42: 295-304
135. Isojarvi JIT, Tauboll E, Tapanainen JS, et al. On the association between valproate and policystic ovary syndrome: a response and an alternative view. Epilepsia 2001; 42: 305-10
136. Herzog AG, Schachter SC. Valproate and policystic ovary syndrome: final thoughts. Epilepsia 2001; 42: 311-5
137. Isojarvi JIT, Rättyä J, Myllylä VV, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998; 43: 446-51
138. Beghi E, Bizzi A, Codegoni AM, et al. Valproate, carnitine metabolism, and biochemical indicators of liver function. Epilepsia 1990; 33: 346-52
139. De Vivo DC, Bohan TP, Coulter DL, et al. L-carnitine supplementation in childhood epilepsy: current perspectives. Epilepsia 1998; 39: 1216-25
140. Saro Y, Kondo I, Ishida S, et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001; 57: 445-9
141. Acharya S, Bussel JB. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol 2000; 22: 62-5
142. Chambers HG, Weinstein CH, Mubarak SJ, et al. The effect of valproic acid on blood loss in patients with cerebral palsy. J Pediatr Orthop 1999; 19: 792-5
143. Anderson GD, Lyn YX, Berge C, et al. Absence of bleeding complications in patients undergoing cortical surgery while receiving valproate treatment. J Neurosurg 1977; 87: 252-6
144. Asconape JJ, Penry JK, Dreifuss FE, et al. Valproate associated pancreatitis. Epilepsia 1993; 34: 177-83
145. Chapman SA, Wachsman GP, Patterson BD. Pancreatitis associated with valproic acid: a review of the literature. Pharmacotherapy 2001; 21: 1549-60
146. Buzan RD, Firestone D, Thomas M, et al. Valproate-associated pancreatitis and cholecystitis in six mentally retarded adults. J Clin Psychiatry 1995; 56: 529-32
147. Moreiras Plaza M, Rodrigues Goyanes G, Cuina L, et al. On the toxicity of valproic acid. Clin Nephrol 1999; 51: 187-9
148. Dreifuss FE, Langer DH, Moline KA, et al. Valproic acid hepatic fatalities. I: US experience since 1984. Neurology 1989; 39: 201-7
149. Bryant III AE, Dreifuss FE. Valproic acid hepatic fatalities. III: US experience since 1986. Neurology 1996; 46: 465-9
150. König SA, Siemes H, Blacker F, et al. Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalities. Epilepsia 1994; 35: 1005-15
151. Bohan TP, Helton E, McDonald I, et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology 2001; 56: 1405-9
152. Raskind JY, El-Chaar GM. The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother 2000; 34: 630-8
153. Ahmed J, Brown C. In-utero exposure to valproate and neural tube defects. Lancet 1996; I: 1392-3
154. Lindhout D, Hoppener RJ, Meinardi H. Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (of carbamazepine). Epilepsia 1984; 25: 77-83
155. Lindhout D, Omtzight JG. Teratogenic effects of antiepileptic drugs: implications for management of epilepsy in women of childbearing age. Epilepsia 1994; 35 Suppl. 4: S19-28
156. Samren EB, Van Duijn CM, Hiilesmaa VK, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European perspective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997; 38: 981-90
157. Samren EB, Van Duijn CM, Christiaens GC, et al. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999; 46: 739-46
158. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999; 33: 145-58
159. Canger R, Battino D, Canevini MP, et al. Malformations in the offspring of women with epilepsy: a prospective study. Epilepsia 1999; 40: 1231-6
160. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001; 344: 1132-8
161. Adab N, Jacoby A, Smith D, et al. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psych 2001; 70: 15-21
162. Zahn CA, Morrell MJ, Collins SD, et al. Management issues for women with epilepsy: a review of the literature. Neurology 1998; 15: 949-56
163. Beghi E, Annegers JF. Pregnancy registries in epilepsy. Epilepsia 2001; 42: 1422-5
164. Nau H, Ralf-Siegbert H, Ehlers K. Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol Toxicol 1991; 69: 310-21
165. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991; 20: 131-7
166. Heaney DC, Shorvon SD, Sander JW, et al. Cost minimization analysis of antiepileptic drugs in newly diagnosed epilepsy in 12 European countries. Epilepsia 2000; 41 Suppl. 5: S37-44
167. Heaney DC, Shorvon SD, Sander JW. An economic appraisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy. Epilepsia 1998; 39 Suppl. 3: S19-25